US Pharma MarketingThe post BD reports nine-month AGILITY trial data for Revello stent appeared first on Medical Device Network.
BD reports nine-month AGILITY trial data for Revello stent
BD has reported nine-month clinical findings from the iliac cohort of its AGILITY Investigational Device Exemption trial of the Revello Vascular Covered Stent. The trial's iliac arm enrolled 120 patients across 28 investigative sites located in Australia, Europe, New Zealand, and the US. The data showed that the trial achieved its primary composite safety and effectiveness endpoint in iliac artery disease. Credit: BD (Becton, Dickinson and Company)/PRNewswire. Becton, Dickinson and Company (BD) has reported nine-month clinical findings from the iliac cohort of its AGILITY Investigational Device Exemption trial of the Revello Vascular Covered Stent. AGILITY global lead principal investigator Sean…
BD has reported nine-month clinical findings from the iliac cohort of its AGILITY Investigational Device Exemption trial of the Revello Vascular Covered Stent.
Source: Medical Device Network